CN108530364B - 一种3-(4-甲基-1h-咪唑-1-基)-5-三氟甲基苯胺单盐酸盐的晶型及其应用 - Google Patents

一种3-(4-甲基-1h-咪唑-1-基)-5-三氟甲基苯胺单盐酸盐的晶型及其应用 Download PDF

Info

Publication number
CN108530364B
CN108530364B CN201810316286.2A CN201810316286A CN108530364B CN 108530364 B CN108530364 B CN 108530364B CN 201810316286 A CN201810316286 A CN 201810316286A CN 108530364 B CN108530364 B CN 108530364B
Authority
CN
China
Prior art keywords
formula
compound
degrees
crystal form
methyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201810316286.2A
Other languages
English (en)
Chinese (zh)
Other versions
CN108530364A (zh
Inventor
牛德良
马伯军
朱占群
万强
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Arizest Shanghai Pharmatech Co ltd
JIANGSU XIDI PHARMACEUTICAL CO Ltd
Shanghai Acebright Pharmaceuticals Group Co ltd
Original Assignee
Anrit (shanghai) Pharmaceutical Technology Co Ltd
SHANGHAI ACEBRIGHT PHARMACEUTICALS GROUP Co Ltd
Jiangsu Creation Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Anrit (shanghai) Pharmaceutical Technology Co Ltd, SHANGHAI ACEBRIGHT PHARMACEUTICALS GROUP Co Ltd, Jiangsu Creation Pharmaceutical Co Ltd filed Critical Anrit (shanghai) Pharmaceutical Technology Co Ltd
Priority to CN201810316286.2A priority Critical patent/CN108530364B/zh
Publication of CN108530364A publication Critical patent/CN108530364A/zh
Priority to PCT/CN2019/081771 priority patent/WO2019196802A1/fr
Priority to US17/046,575 priority patent/US11414388B2/en
Priority to EP19785947.3A priority patent/EP3782988A4/fr
Application granted granted Critical
Publication of CN108530364B publication Critical patent/CN108530364B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
    • C07D233/58—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
    • C07D233/61—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms with hydrocarbon radicals, substituted by nitrogen atoms not forming part of a nitro radical, attached to ring nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
CN201810316286.2A 2018-04-10 2018-04-10 一种3-(4-甲基-1h-咪唑-1-基)-5-三氟甲基苯胺单盐酸盐的晶型及其应用 Active CN108530364B (zh)

Priority Applications (4)

Application Number Priority Date Filing Date Title
CN201810316286.2A CN108530364B (zh) 2018-04-10 2018-04-10 一种3-(4-甲基-1h-咪唑-1-基)-5-三氟甲基苯胺单盐酸盐的晶型及其应用
PCT/CN2019/081771 WO2019196802A1 (fr) 2018-04-10 2019-04-08 Forme cristalline du monochlorhydrate de 3-(4-méthyl-1h-imidazol-1-yl)-5-trifluorométhylaniline et utilisation associée
US17/046,575 US11414388B2 (en) 2018-04-10 2019-04-08 Crystal form of 3-(4-methyl-1h-imidazol-1-yl)-5-trifluoromethylaniline monohydrochloride and use thereof
EP19785947.3A EP3782988A4 (fr) 2018-04-10 2019-04-08 Forme cristalline du monochlorhydrate de 3-(4-méthyl-1h-imidazol-1-yl)-5-trifluorométhylaniline et utilisation associée

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN201810316286.2A CN108530364B (zh) 2018-04-10 2018-04-10 一种3-(4-甲基-1h-咪唑-1-基)-5-三氟甲基苯胺单盐酸盐的晶型及其应用

Publications (2)

Publication Number Publication Date
CN108530364A CN108530364A (zh) 2018-09-14
CN108530364B true CN108530364B (zh) 2020-01-21

Family

ID=63479866

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201810316286.2A Active CN108530364B (zh) 2018-04-10 2018-04-10 一种3-(4-甲基-1h-咪唑-1-基)-5-三氟甲基苯胺单盐酸盐的晶型及其应用

Country Status (4)

Country Link
US (1) US11414388B2 (fr)
EP (1) EP3782988A4 (fr)
CN (1) CN108530364B (fr)
WO (1) WO2019196802A1 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112939945A (zh) * 2021-02-25 2021-06-11 深圳市泰力生物医药有限公司 尼洛替尼的晶型、使用该晶型制备的活性药物和药物组合物

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108530364B (zh) * 2018-04-10 2020-01-21 江苏创诺制药有限公司 一种3-(4-甲基-1h-咪唑-1-基)-5-三氟甲基苯胺单盐酸盐的晶型及其应用
CN116102540A (zh) * 2023-01-05 2023-05-12 浙江工业大学 两种尼洛替尼游离碱新晶型及其制备方法

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0215676D0 (en) * 2002-07-05 2002-08-14 Novartis Ag Organic compounds
MY146795A (en) * 2005-06-09 2012-09-28 Novartis Ag Process for the synthesis of organic compounds
GT200600207A (es) 2005-06-09 2007-01-15 Novartis Ag Proceso para la síntesis de compuestos orgánicos
US20100016590A1 (en) * 2008-07-17 2010-01-21 Teva Pharmaceutical Industries Ltd. Nilotinib intermediates and preparation thereof
CN102321073A (zh) * 2011-08-12 2012-01-18 西安交通大学 一种尼罗替尼的制备方法
CN108530364B (zh) * 2018-04-10 2020-01-21 江苏创诺制药有限公司 一种3-(4-甲基-1h-咪唑-1-基)-5-三氟甲基苯胺单盐酸盐的晶型及其应用

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112939945A (zh) * 2021-02-25 2021-06-11 深圳市泰力生物医药有限公司 尼洛替尼的晶型、使用该晶型制备的活性药物和药物组合物

Also Published As

Publication number Publication date
WO2019196802A1 (fr) 2019-10-17
US11414388B2 (en) 2022-08-16
US20210139433A1 (en) 2021-05-13
EP3782988A4 (fr) 2022-03-23
CN108530364A (zh) 2018-09-14
EP3782988A1 (fr) 2021-02-24

Similar Documents

Publication Publication Date Title
US8217061B2 (en) Polymorphs of sorafenib tosylate and sorafenib hemi-tosylate, and processes for preparation thereof
KR101377778B1 (ko) 엘트롬보팩 및 엘트롬보팩 염의 다형체 및 이의 제조 방법
CN108530364B (zh) 一种3-(4-甲基-1h-咪唑-1-基)-5-三氟甲基苯胺单盐酸盐的晶型及其应用
EP2571863B1 (fr) Sels de nilotinib et leurs formes cristallines
JP6556293B2 (ja) 純粋なニロチニブ及びその塩の調製のための方法
CN101203494A (zh) 合成经取代3-氰基喹啉和其中间物的方法
JP2002509919A (ja) ピリダジノン化合物塩酸塩及びその製造法
EP1912973A2 (fr) Formes cristallines de 4-methyl-n-[3-(4-methyl-imidazol-1-yl)-5-trifluoromethyl-phenyl]-3-(4-pyridin-3-yl-pyrimidin-2-ylamino)-benzamide
JP5078993B2 (ja) １−（３，４−ジクロロベンジル）−５−オクチルビグアナイドまたはその塩の製造方法
EP4046687A1 (fr) Procédé de production de la centanafadine
JP6967143B2 (ja) ガドブトロール中間体及びこれを用いたガドブトロールの製造方法
AU2019398756B2 (en) Crystalline forms of 1-[(3R,4S)-4-cyanotetrahydropyran-3-yl]-3-[(2-fluoro-6-methoxy-4-pyridyl)amino]pyrazole-4-carboxamide
CN109810052B (zh) 一种高选择性的阿帕替尼的简便制备方法
TW202210486A (zh) 一種製備ｇｌｐ—１受體激動劑的方法
CN107814769B (zh) 一种博舒替尼的纯化方法
JP5501054B2 (ja) ３，３−ジアミノアクリル酸（１−ジフェニルメチルアゼチジン−３−イル）エステル酢酸塩の製造方法
CN112679473B (zh) 来那替尼中间体晶体、制备方法及其用途
CN118561748B (zh) 一种制备2-氨基-4-氯-5-硝基吡啶的方法
WO2024172778A1 (fr) Nouveau polymorphe d'hémifumarate de ruxolitinib et procédé de préparation
WO2023121574A1 (fr) Nouveau polymorphe d'hémifumarate de ruxolitinib et son procédé de préparation
CN105523994A (zh) 甲磺酸洛美他派晶型iii
WO2023140809A1 (fr) Nouveau polymorphe de vismodégib et procédé de préparation
CN103923063A (zh) 一种苯甲酸阿格列汀的新晶型及其制备方法
CN112778207A (zh) 一种盐酸尼洛替尼原料药杂质及其制备方法
CN106946846A (zh) 达比加群酯新中间体及其制备方法

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant
CP03 Change of name, title or address
CP03 Change of name, title or address

Address after: 226200 No.3 Jiangfeng Road, Qidong life and Health Industrial Park, Nantong City, Jiangsu Province

Patentee after: JIANGSU XIDI PHARMACEUTICAL Co.,Ltd.

Patentee after: ARIZEST (SHANGHAI) PHARMATECH Co.,Ltd.

Patentee after: SHANGHAI ACEBRIGHT PHARMACEUTICALS GROUP Co.,Ltd.

Address before: 226200 Jiangfeng Road, Binjiang Fine Chemical Park, Qidong Economic Development Zone, Nantong City, Jiangsu Province

Patentee before: JIANGSU ACEBRIGHT PHARMACEUTICALS Co.,Ltd.

Patentee before: ARIZEST (SHANGHAI) PHARMATECH Co.,Ltd.

Patentee before: SHANGHAI ACEBRIGHT PHARMACEUTICALS GROUP Co.,Ltd.